Document:

Form of Notice of Grant-Non-Exempt Employee

 Exhibit 10.6 
 NON-EXEMPT EMPLOYEE 
 UNDER FAIR LABOR STANDARDS ACT 

WHITEGLOVE HOUSE CALL HEALTH, INC. 
 NOTICE OF GRANT OF STOCK OPTION 
 Notice is hereby given of the following
option grant (the “Option”) to purchase shares (the “Option Shares”) of the Common Stock of Whiteglove House Call Health, Inc., a Texas corporation (the “Company”): 

 

			
	 Optionee:
	  	«name»
                                         
                                   
		
	 Grant Date:
	  	«granted»                         
                                         
                      
		
	 Vesting Commencement Date:
	  	«VDate»                          
              
		
	 Exercise Price:
	  	$ «exc_price»
                                         
                per share
		
	 Number of Option Shares:
	  	«Shares_Granted»
                                         
    shares of Common Stock
		
	 Expiration Date:
	  	«expiration»                         
               
		
	 Type of Option:
	  	«ISO»     Incentive Stock Option
		
		  	«NSO»     Non-Statutory Stock Option

 Date Exercisable: The Option shall become exercisable for all the Option Shares upon the Optionee’s completion of six (6) months of Service measured from the Grant Date. 

Vesting Schedule: The Option Shares shall initially be unvested and subject to repurchase by the Company at the lower of
(i) the Exercise Price paid per share or (ii) the Fair Market Value per share at the time of Optionee’s cessation of Service. Optionee shall acquire a vested interest in, and the Company’s repurchase right shall accordingly lapse
with respect to, (y) one-fourth (1/4th) of the Option Shares on the first anniversary of the Vesting Commencement Date and (z) an additional one forty-eighth (1/48th) of the Option Shares on the corresponding day of each calendar
month thereafter or, if such calendar month does not have a corresponding day, on the last day of such calendar month. The Option shall not become exercisable for any additional Option Shares following the Optionee’s cessation of Service,
except to the extent (if any) specifically authorized by the Plan Administrator in its sole discretion pursuant to an express written agreement with Optionee. 

 Optionee understands and agrees that the Option is granted subject to and in accordance with
the terms of the Whiteglove House Call Health, Inc. 2007 Stock Option/Stock Issuance Plan (the “Plan”). Optionee further agrees to be bound by the terms of the Plan and the terms of the Option as set forth in the Stock Option
Agreement attached hereto as Exhibit A and the Code Section 409A Waiver and Release attached hereto as Exhibit B. Optionee understands that any Option Shares purchased under the Option will be subject to the terms set forth in the
Stock Purchase Agreement attached hereto as Exhibit C. Optionee hereby acknowledges receipt of a copy of the Plan in the form attached hereto as Exhibit D and receipt of “Questions and Answers about Option Grants” from the
Company. 
 TRANSFER RESTRICTIONS. OPTIONEE HEREBY AGREES THAT ALL OPTION SHARES ACQUIRED UPON THE EXERCISE OF THE
OPTION SHALL BE SUBJECT TO CERTAIN REPURCHASE RIGHTS AND RIGHTS OF FIRST REFUSAL EXERCISABLE BY THE COMPANY AND ITS ASSIGNS. THE TERMS OF SUCH RIGHTS ARE SPECIFIED IN THE ATTACHED STOCK PURCHASE AGREEMENT. 

At Will Employment. Nothing in this Notice or in the attached Stock Option Agreement or Plan shall confer upon Optionee any right
to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly
reserved by each, to terminate Optionee’s Service at any time for any reason, with or without cause. 
 Definitions.
All capitalized terms in this Notice shall have the meaning assigned to them in this Notice, in the attached Stock Option Agreement or in the Plan. 
  

									
	DATED:                      ,
            	 		 	WHITEGLOVE HOUSE CALL HEALTH, INC.
					
		 		 		 	By:	 	 
					
		 		 		 	Title:	 	 
				
		 		 		 	OPTIONEE
				
		 		 		 	 
		 		 		 	«name»	 	
					
		 		 		 	Address:	 	 
		 		 		 		 	 
		 		 		 	Phone:	 	 
		 		 		 	Email:	 	 

 Attachments:

 Exhibit A – Stock Option Agreement 
 Exhibit B – Code Section 409A Waiver and Release 
 Exhibit C – Stock
Purchase Agreement 
 Exhibit D – 2007 Stock Option/Stock Issuance Plan 

  
 2 

 EXHIBIT A 
 STOCK OPTION AGREEMENT 

 NON-EXEMPT EMPLOYEE 

Whiteglove House Call Health, Inc. 
 STOCK OPTION AGREEMENT 
 RECITALS 

A. The Board has adopted the 2007 Stock Option/Stock Issuance Plan (the “Plan”) for the purpose of retaining the
services of selected Employees, non-employee members of the Board or the board of directors of any Parent or Subsidiary and consultants and other independent advisors in the service of the Company (or any Parent or Subsidiary). 

B. Optionee is to render valuable services to the Company (or a Parent or Subsidiary), and this Agreement is executed pursuant to, and is
intended to carry out the purposes of, the Plan in connection with the Company’s grant of an option to Optionee. 
 C. All
capitalized terms in this Agreement not defined herein shall have the meaning assigned to them in the Plan. 
 NOW, THEREFORE,
it is hereby agreed as follows: 
 1. Grant of Option. The Company hereby grants to Optionee, as of the date of grant of
the option (“Grant Date”) as specified in the Notice of Grant of Stock Option accompanying the Agreement, pursuant to which Optionee has been informed of the basic terms of the option evidenced hereby (the “Grant
Notice”), an option to purchase up to the number of shares of Common Stock subject to the option (the “Option Shares”) specified in the Grant Notice. The Option Shares shall be purchasable from time to time
during the option term specified in Paragraph 2 at the exercise price payable per Option Share as specified in the Grant Notice (the “Exercise Price”). 
 2. Option Term. This option shall have a term of ten (10) years measured from the Grant Date and shall accordingly expire at the close of business on the date on which the option expires as
specified in the Grant Notice (the “Expiration Date”), unless sooner terminated in accordance with Paragraph 5 or 6. 
 3. Limited Transferability. 
 (a) This option shall be
neither transferable nor assignable by Optionee other than by will or the laws of inheritance following Optionee’s death and may be exercised, during Optionee’s lifetime, only by Optionee. However, Optionee may designate one or more
persons as the beneficiary or beneficiaries of this option, and this option shall, in accordance with such designation, automatically be transferred to such beneficiary or beneficiaries upon the Optionee’s death while holding this option. Such
beneficiary or beneficiaries shall take the transferred option subject to all the terms and conditions of this Agreement, including (without limitation) the limited time period during which this option may, pursuant to Paragraph 5, be exercised
following Optionee’s death. 

  
 Exhibit A -
Page 1 

 (b) If this option is designated a Non-Statutory Option in the Grant Notice,
then this option may be assigned in whole or in part during Optionee’s lifetime to one or more of Optionee’s Family Members or to a trust established for the exclusive benefit of Optionee and/or one or more such Family Members, to the
extent such assignment is in connection with the Optionee’s estate plan or pursuant to a domestic relations order. The assigned portion shall be exercisable only by the person or persons who acquire a proprietary interest in the option pursuant
to such assignment. The terms applicable to the assigned portion shall be the same as those in effect for this option immediately prior to such assignment. 
 4. Dates of Exercise. This option shall become exercisable for the Option Shares in one or more installments as specified in the Grant Notice. As the option becomes exercisable for such
installments, those installments shall accumulate, and the option shall remain exercisable for the accumulated installments until the Expiration Date or sooner termination of the option term under Paragraph 5 or 6. 

5. Cessation of Service. The option term specified in Paragraph 2 shall terminate (and this option shall cease to be outstanding)
prior to the Expiration Date should any of the following provisions become applicable: 
 (a) Should Optionee
cease to remain in Service for any reason (other than death, Disability or Misconduct) while this option is outstanding, then Optionee (or any person or persons to whom this option is transferred pursuant to a permitted transfer under Paragraph 3)
shall have a period of three (3) months (commencing with the date of such cessation of Service) during which to exercise this option, but in no event shall this option be exercisable at any time after the Expiration Date. 

(b) Should Optionee die while this option is outstanding, then the personal representative of Optionee’s estate or
the person or persons to whom the option is transferred pursuant to Optionee’s will or the laws of inheritance following Optionee’s death or, if applicable, the person to whom the option is transferred during Optionee’s lifetime
pursuant to a permitted transfer under Paragraph 3 shall have the right to exercise this option. However, if Optionee dies while holding this option and has an effective beneficiary designation in effect for this option at the time of his or her
death, then the designated beneficiary or beneficiaries shall have the exclusive right to exercise this option following Optionee’s death. Any such right to exercise this option shall lapse, and this option shall cease to be outstanding, upon
the earlier of (i) the expiration of the twelve (12)-month period measured from the date of Optionee’s death or (ii) the Expiration Date. 
 (c) Should Optionee cease Service by reason of Disability while this option is outstanding, then Optionee (or any person or persons to whom this option is transferred pursuant to a permitted transfer
under Paragraph 3) shall have a period of twelve (12) months (commencing with the date of such cessation of Service) during which to exercise this option. In no event shall this option be exercisable at any time after the Expiration Date.

 Note: Exercise of this option on a date later than three (3) months following cessation of Service due to
Disability will result in loss of favorable Incentive Option treatment, unless such Disability constitutes Permanent Disability. In the event that Incentive Option treatment is not available, this option will be taxed as a Non-Statutory Option upon
exercise. 

  
 Exhibit A -
Page 2 

 (d) During the limited period of post-Service exercisability, this option
may not be exercised in the aggregate for more than the number of Option Shares in which Optionee is, at the time of Optionee’s cessation of Service, vested pursuant to the vesting schedule specified in the Grant Notice pursuant to which the
Optionee is to vest in the Option Shares in a series of installments over his or her period of Service (the “Vesting Schedule”) or the special vesting acceleration provisions of Paragraph 6. No additional Option Shares shall
vest, whether pursuant to the normal Vesting Schedule specified in the Grant Notice or the special vesting acceleration provisions of Paragraph 6, following Optionee’s cessation of Service, except to the extent (if any) specifically authorized
by the Plan Administrator pursuant to an express written agreement with Optionee. Upon the expiration of such limited exercise period or (if earlier) upon the Expiration Date, this option shall terminate and cease to be outstanding for any vested
Option Shares for which the option has not been exercised. 
 (e) Should Optionee’s Service be terminated
for Misconduct or should Optionee otherwise engage in Misconduct while this option is outstanding, then this option shall terminate immediately and cease to remain outstanding. 

6. Change in Control. 
 (a) Should a Change in Control occur during Optionee’s period of Service, then the Option Shares at the time subject to this option but not otherwise vested shall automatically vest in full so that
this option shall, immediately prior to the effective date of the Change in Control, become exercisable for all of the Option Shares as fully vested shares and may be exercised for any or all of those Option Shares as vested shares. However, the
Option Shares shall not vest on such an accelerated basis if and to the extent: (i) this option is assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in
Control transaction and the Company’s repurchase rights with respect to the unvested Option Shares are assigned to such successor corporation (or parent thereof) or otherwise continued in effect or (ii) this option is to be replaced with a
cash retention program of the successor corporation which preserves the spread existing on the unvested Option Shares at the time of the Change in Control (the excess of the Fair Market Value of those Option Shares over the Exercise Price payable
for such shares) and provides for subsequent payout of that spread in accordance with the same Vesting Schedule applicable to those unvested Option Shares as set forth in the Grant Notice. 

(b) Immediately following the Change in Control, this option shall terminate and cease to be outstanding, except to the
extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction. 

  
 Exhibit A -
Page 3 

 (c) If this option is assumed in connection with a Change in Control or
otherwise continued in effect, then this option shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to Optionee in consummation of such Change in
Control had the option been exercised immediately prior to such Change in Control, and appropriate adjustments shall also be made to the Exercise Price, provided the aggregate Exercise Price shall remain the same. To the extent that the
actual holders of the Company’s outstanding Common Stock receive cash consideration for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption or continuation of this
option, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control. 

(d) This Agreement shall not in any way affect the right of the Company to adjust, reclassify, reorganize or otherwise
change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets. 
 7. Adjustment in Option Shares. In the event of any of the following transactions affecting the outstanding Common Stock as a class without the Company’s receipt of consideration: any stock
split, stock dividend, spin-off transaction, extraordinary distribution (whether in cash, securities or other property), recapitalization, combination of shares, exchange of shares or other similar transaction affecting the Common Stock without the
Company’s receipt of consideration, then equitable adjustments shall be made to (i) the total number and/or class of securities subject to this option and (ii) the Exercise Price. The adjustments shall be made by the Plan
Administrator in such manner as the Plan Administrator deems appropriate in order to reflect such change and thereby preclude a dilution or enlargement of benefits hereunder. 
 8. Stockholder Rights. The holder of this option shall not have any stockholder rights with respect to the Option Shares until such person shall have exercised the option, paid the Exercise Price
and become the record holder of the purchased shares. 
 9. Manner of Exercising Option. 

(a) In order to exercise this option with respect to all or any part of the Option Shares for which this option is at the
time exercisable, Optionee (or any other person or persons exercising the option) must take the following actions: 
 (i) Execute and deliver to the Company a stock purchase agreement in substantially the form of Exhibit C to the Grant Notice (a “Purchase Agreement”) for the Option Shares
for which the option is exercised. 
 (ii) Pay the aggregate Exercise Price for the purchased shares in one or
more of the following forms: 
 (A) cash or check made payable to the Company; or 

(B) a promissory note payable to the Company, but only to the extent authorized by the Plan Administrator in accordance
with Paragraph 14. 

  
 Exhibit A -
Page 4 

 Should the Common Stock be registered under Section 12 of the 1934 Act
at the time the option is exercised, then the Exercise Price may also be paid as follows: 
 (C) in shares of
Common Stock valued at Fair Market Value on the date on which the options shall have been exercised in accordance with this Paragraph 9 (the “Exercise Date”) and held by Optionee (or any other person or persons exercising the
option) for the period (if any) necessary to avoid a charge to the Company’s earnings for financial reporting purposes; or 
 (D) to the extent the option is exercised for vested Option Shares, through a special sale and remittance procedure pursuant to which Optionee (or any other person or persons exercising the option) shall
concurrently provide irrevocable instructions (a) to a brokerage firm (reasonably satisfactory to the Company for purposes of administering such procedure in compliance with any applicable pre-clearance or pre-notification requirements) to
effect the immediate sale of the purchased shares and remit to the Company, out of the sale proceeds available on the settlement date, sufficient funds to cover the aggregate Exercise Price payable for the purchased shares plus all applicable income
and employment taxes required to be withheld by the Company by reason of such exercise and (b) to the Company to deliver the certificates for the purchased shares directly to such brokerage firm on such settlement date in order to complete the
sale. 
 Except to the extent the sale and remittance procedure is utilized in connection with the option
exercise, payment of the Exercise Price must accompany the Purchase Agreement delivered to the Company in connection with the option exercise. 
 (iii) Furnish to the Company appropriate documentation that the person or persons exercising the option (if other than Optionee) have the right to exercise this option. 

(iv) Execute and deliver to the Company such written representations as may be requested by the Company in order for it to
comply with the applicable requirements of applicable securities laws. 
 (v) Make appropriate arrangements with
the Company (or Parent or Subsidiary employing or retaining Optionee) for the satisfaction of all applicable income and employment tax withholding requirements applicable to the option exercise. 

(b) As soon as practical after the Exercise Date, the Company shall issue to or on behalf of Optionee (or any other person
or persons exercising this option) a certificate for the purchased Option Shares, with the appropriate legends affixed thereto. 
 (c) In no event may this option be exercised for any fractional shares. 

  
 Exhibit A -
Page 5 

 10. REPURCHASE RIGHTS. ALL OPTION SHARES ACQUIRED UPON THE EXERCISE OF THIS OPTION
SHALL BE SUBJECT TO CERTAIN RIGHTS OF THE COMPANY AND ITS ASSIGNS TO REPURCHASE THOSE SHARES IN ACCORDANCE WITH THE TERMS SPECIFIED IN THE PURCHASE AGREEMENT. 
 11. Compliance with Laws and Regulations. 
 (a) The exercise
of this option and the issuance of the Option Shares upon such exercise shall be subject to compliance by the Company and Optionee with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange (or
the Nasdaq National Market, if applicable) on which the Common Stock may be listed for trading at the time of such exercise and issuance. 
 (b) The inability of the Company to obtain approval from any regulatory body having authority deemed by the Company to be necessary to the lawful issuance and sale of any Common Stock pursuant to this
option shall relieve the Company of any liability with respect to the non-issuance or sale of the Common Stock as to which such approval shall not have been obtained. The Company, however, shall use its best efforts to obtain all such approvals.

 12. Successors and Assigns. Except to the extent otherwise provided in Paragraphs 3 and 6, the provisions of this
Agreement shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and Optionee, Optionee’s assigns and the legal representatives, heirs and legatees of Optionee’s estate. 

13. Notices. Any notice required to be given or delivered to the Company under the terms of this Agreement shall be in writing and
addressed to the Company at its principal corporate offices. Any notice required to be given or delivered to Optionee shall be in writing and addressed to Optionee at the address indicated below Optionee’s signature line on the Grant Notice.
All notices shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified. 

Optionee generally consents to the delivery of any notice pursuant to the Texas Business Organizations Code (the
“TBOC”), as amended or superseded from time to time, by electronic message pursuant to Section 6.051 of the TBOC (“Electronic Notice”) at the electronic mail address or the facsimile number as set
forth in the books of the Company. To the extent that any notice given via electronic message is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address
has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. Optionee agrees to promptly notify the Company of any change in Optionee’s electronic mail address, but failure to do so shall not
affect the foregoing. 
 14. Financing. The Plan Administrator may, in its absolute discretion and without any obligation
to do so, permit Optionee to pay the Exercise Price for the purchased Option Shares by delivering a full-recourse promissory note bearing interest at a market rate and secured by those Option Shares. The payment schedule in effect for any such
promissory note shall be established by the Plan Administrator in its sole discretion. 

  
 Exhibit A -
Page 6 

 15. Construction. This Agreement and the option evidenced hereby are made and granted
pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan. All decisions of the Plan Administrator with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on
all persons having an interest in this option. 
 16. Governing Law. The interpretation, performance and enforcement of
this Agreement shall be governed by the laws of the State of Texas without resort to that state’s conflict-of-laws rules. 

17. Stockholder Approval. If the Option Shares covered by this Agreement exceed, as of the Grant Date, the number of shares of
Common Stock which may be issued under the Plan as last approved by the stockholders, then this option shall be void with respect to such excess shares, unless stockholder approval of an amendment sufficiently increasing the number of shares of
Common Stock issuable under the Plan is obtained in accordance with the provisions of the Plan. 
 18. Additional Terms
Applicable to an Incentive Option. In the event this option is designated an Incentive Option in the Grant Notice, the following terms and conditions shall also apply to the grant: 

(a) This option shall cease to qualify for favorable tax treatment as an Incentive Option if (and to the extent) this
option is exercised for one or more Option Shares: (i) more than three (3) months after the date Optionee ceases to be an Employee for any reason other than death or Permanent Disability or (ii) more than twelve (12) months after
the date Optionee ceases to be an Employee by reason of Permanent Disability. 
 (b) This option shall not become
exercisable in the calendar year in which granted if (and to the extent) the aggregate Fair Market Value (determined at the Grant Date) of the Common Stock for which this option would otherwise first become exercisable in such calendar year would,
when added to the aggregate value (determined as of the respective date or dates of grant) of the Common Stock and any other securities for which one or more other Incentive Options granted to Optionee prior to the Grant Date (whether under the Plan
or any other option plan of the Company or any Parent or Subsidiary) first become exercisable during the same calendar year, exceed One Hundred Thousand Dollars ($100,000) in the aggregate. To the extent the exercisability of this option is deferred
by reason of the foregoing limitation, the deferred portion shall become exercisable in the first calendar year or years thereafter in which the One Hundred Thousand Dollar ($100,000) limitation of this Paragraph 18(b) would not be contravened, but
such deferral shall in all events end immediately prior to the effective date of a Change in Control in which this option is not to be assumed or otherwise continued in effect, whereupon the option shall become immediately exercisable as a
Non-Statutory Option for the deferred portion of the Option Shares. 
 (c) Should Optionee hold, in addition to
this option, one or more other options to purchase Common Stock which become exercisable for the first time in the same calendar year as this option, then for purposes of the foregoing limitations on the exercisability of such options as Incentive
Options, this option and each of those other options shall be deemed to become first exercisable in that calendar year on the basis of the chronological order in which they were granted, except to the extent otherwise provided under applicable law
or regulation. 

  
 Exhibit A -
Page 7 

 EXHIBIT B 
 CODE SECTION 409A WAIVER AND RELEASE 

 NON-EXEMPT EMPLOYEE 

Whiteglove House Call Health, Inc. 
 CODE SECTION 409A WAIVER AND RELEASE 
 THIS WAIVER AND RELEASE (this
“Waiver”) made as of this              day of
                        , 20     , by «name», the holder of a stock option under
the Company’s 2007 Stock Option/Stock Issuance Plan. 
 All capitalized terms in this Waiver not defined herein shall have
the meaning assigned to them in the Notice to which this Waiver is attached or in the Plan. 
 Optionee hereby agrees and
acknowledges that the Company’s Board has taken reasonable steps to value the Common Stock and to set the Exercise Price at the Fair Market Value per share of Common Stock on the Grant Date so that the Option will not be treated as an item of
deferred compensation subject to Code Section 409A. However, because the Common Stock is not readily tradable on an established securities market, there can be no assurance that the Exercise Price is at least equal to the Fair Market Value per
share of Common Stock on the Grant Date. Were the Internal Revenue Service to conclude that the Exercise Price is in fact less than such Fair Market Value and that the Option is accordingly subject to Code Section 409A, then Optionee would be
subject the following adverse tax consequences: 
 (i) As the Option vests in accordance with the Vesting
Schedule, Optionee would immediately recognize taxable income for federal income tax purposes equal to the amount by which the Fair Market Value of the Option Shares which vest at that time exceeds the Exercise Price payable for those shares. The
Company would also have to collect from Optionee the federal income and employment taxes which must be withheld on that income. Taxation would occur in this manner even though the Option remains unexercised. 

(ii) Optionee may also be subject to additional income taxation and withholding taxes on any subsequent increases to the
Fair Market Value of the Option Shares purchasable under the vested Option until the Option is exercised or cancelled as to those Option Shares. 
 (iii) In addition to normal income taxes payable as the Option vests, Optionee would also be subject to an additional tax penalty equal to 20% of the amount of income Optionee recognizes under Code
Section 409A when the Option vests and may also be subject to such penalty as the underlying Option Shares subsequently increase in Fair Market Value over the period the Option continues to remain outstanding. 

(iv) There will also be interest penalties if the resulting taxes are not paid on a timely basis. 

Optionee hereby further agrees and acknowledges that Optionee will incur the same tax consequences, including (without limitation) a
second 20% penalty tax, under California income tax laws if Optionee is a resident of the State of California or is otherwise subject to California income taxation. If the Optionee is a resident of any other state, he or she accepts the risk of any
unfavorable tax consequences under the laws of that state applicable to options granted with an Exercise Price less than the Fair Market Value of the Option Shares on the Grant Date. 

  
 Exhibit B -
Page 1 

 Optionee hereby agrees to bear the entire risk of such adverse federal and state tax
consequences in the event the Option is deemed to be subject to Code Section 409A and hereby knowingly and voluntarily, in consideration for the grant of the Option, waives and releases any and all claims or causes of action that Optionee might
otherwise have against the Company and/or the Board, officers, employees or stockholders arising from or relating to the tax treatment of the Option under Code Section 409A and the corresponding provisions of any applicable state income tax
laws (including, without limitation, California income tax laws) and shall not seek any indemnification or other recovery of damages against the Company and/or the Board, officers, employees or stockholders with respect to any adverse federal and
state tax consequences or other related costs and expenses Optionee may in fact incur under Code Section 409A (or the corresponding provisions of state income tax laws) as a result of the Option. 

IN WITNESS WHEREOF, the undersigned Optionee has executed this Waiver on the date and year first indicated above. 

 

			
	OPTIONEE
	
	 
	«name»	 	
		 	
	Address:	 	 
		 	 

  
 Exhibit B -
Page 2 

 EXHIBIT C 
 STOCK PURCHASE AGREEMENT 

 NON-EXEMPT EMPLOYEE 

Whiteglove House Call Health, Inc. 
 STOCK PURCHASE AGREEMENT 
 AGREEMENT made this
             day of                     , 20
     by and between Whiteglove House Call Health, Inc., a Texas corporation, and «name», Optionee under the Company’s 2007 Stock Option/Stock Issuance Plan. 

All capitalized terms in this Agreement shall have the meaning assigned to them in this Agreement or in the Plan attached as Exhibit
D to the Notice of Grant to which this Agreement relates. 
  

	A.	EXERCISE OF OPTION 

 1.
Exercise. Optionee hereby purchases              shares of Common Stock (the “Purchased Shares”) pursuant to that certain option (the
“Option”) granted Optionee on «granted» (the “Grant Date”) to purchase up to              shares of Common Stock (the
“Option Shares”) under the Plan at the exercise price of $             per share (the “Exercise Price”). 

2. Payment. Concurrently with the delivery of this Agreement to the Company, Optionee shall pay the Exercise Price for the
Purchased Shares in accordance with the provisions of all agreements and other documents evidencing the Option (the “Option Agreement”) and shall deliver whatever additional documents may be required by the Option Agreement
as a condition for exercise, together with a duly-executed blank Assignment Separate from Certificate (in the form attached hereto as Exhibit I) with respect to the Purchased Shares. 

3. Stockholder Rights. Until such time as the Company exercises the Repurchase Right or the First Refusal Right, Optionee (or any
successor in interest) shall have all the rights of a stockholder (including voting, dividend and liquidation rights) with respect to the Purchased Shares, subject, however, to the transfer restrictions of Articles B and C. 

4. Information. Optionee believes it has received all the information it considers necessary or appropriate for deciding whether
to purchase the Purchased Shares. Optionee further represents that such Optionee has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Purchased Shares and the
business, properties, prospects and financial condition of the Company. Optionee acknowledges that it has been furnished separately “Questions and Answers about Option Grants” by the Company. 

 

	B.	SECURITIES LAW COMPLIANCE 

1. Restricted Securities. The Purchased Shares have not been registered under the Securities Act of 1933, as amended (the
“1933 Act”) and are being issued to Optionee in reliance upon the exemption from such registration provided by Rule 701 of the Securities and Exchange Commission (the “SEC”) for stock issuances under
compensatory benefit plans such as the Plan. Optionee hereby confirms that Optionee has been informed that the Purchased Shares are restricted securities under the 1933 Act and may not be resold or transferred unless the

  
 Exhibit C -
Page 1 

 
Purchased Shares are first registered under the federal securities laws or unless an exemption from such registration is available. Accordingly, Optionee hereby acknowledges that Optionee is
acquiring the Purchased Shares for investment purposes only and not with a view to resale and is prepared to hold the Purchased Shares for an indefinite period and that Optionee is aware that SEC Rule 144 issued under the 1933 Act which exempts
certain resales of unrestricted securities is not presently available to exempt the resale of the Purchased Shares from the registration requirements of the 1933 Act. 
 2. Restrictions on Disposition of Purchased Shares. Optionee shall make no disposition of the Purchased Shares (other than a Permitted Transfer) unless and until there is compliance with all of the
following requirements: 
 (i) Optionee shall have provided the Company with a written summary of the terms and
conditions of the proposed disposition. 
 (ii) Optionee shall have complied with all requirements of this
Agreement applicable to the disposition of the Purchased Shares. 
 (iii) Optionee shall have provided the
Company with written assurances, in form and substance satisfactory to the Company, that (a) the proposed disposition does not require registration of the Purchased Shares under the 1933 Act or (b) all appropriate action necessary for
compliance with the registration requirements of the 1933 Act or any exemption from registration available under the 1933 Act (including Rule 144) has been taken. 
 The Company shall not be required (i) to transfer on its books any Purchased Shares which have been sold or transferred in violation of the provisions of this Agreement or (ii) to treat as the
owner of the Purchased Shares, or otherwise to accord voting, dividend or liquidation rights to, any transferee to whom the Purchased Shares have been transferred in contravention of this Agreement. 

3. Restrictive Legends. The stock certificates for the Purchased Shares shall be endorsed with one or more of the following
restrictive legends: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THE
SHARES MAY NOT BE SOLD OR OFFERED FOR SALE IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SHARES UNDER SUCH ACT, (B) A ‘NO ACTION’ LETTER OF THE SECURITIES AND EXCHANGE COMMISSION WITH RESPECT TO SUCH SALE OR
OFFER OR (C) SATISFACTORY ASSURANCES TO THE COMPANY THAT REGISTRATION UNDER SUCH ACT IS NOT REQUIRED WITH RESPECT TO SUCH SALE OR OFFER. 
 THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN REPURCHASE RIGHTS AND RIGHTS OF FIRST REFUSAL GRANTED TO THE COMPANY AND ACCORDINGLY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED,
OR IN ANY 

  
 Exhibit C -
Page 2 

 
MANNER DISPOSED OF EXCEPT IN CONFORMITY WITH THE TERMS OF A STOCK PURCHASE AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER OF THE SHARES (OR THE PREDECESSOR IN INTEREST TO THE SHARES). A
COPY OF SUCH AGREEMENT IS MAINTAINED AT THE COMPANY’S PRINCIPAL CORPORATE OFFICES. 
  

	C.	TRANSFER RESTRICTIONS 

 1.
Restriction on Transfer. Except for any Permitted Transfer, Optionee shall not transfer, assign, encumber or otherwise dispose of any of the Purchased Shares which are subject to the Repurchase Right. In addition, Purchased Shares which are
released from the Repurchase Right shall not be transferred, assigned, encumbered or otherwise disposed of in contravention of the First Refusal Right or the Market Stand-Off. 
 2. Transferee Obligations. Each person (other than the Company) to whom the Purchased Shares are transferred by means of a Permitted Transfer must, as a condition precedent to the validity of such
transfer, acknowledge in writing to the Company that such person is bound by the provisions of this Agreement and that the transferred shares are subject to (i) the Repurchase Right, (ii) the First Refusal Right and (iii) the Market
Stand-Off, to the same extent such shares would be so subject if retained by Optionee. 
 3. Market Stand-Off.

 (a) In connection with any underwritten public offering by the Company of its equity securities pursuant to an
effective registration statement filed under the 1933 Act, including the Company’s initial public offering, Optionee and all subsequent holders of the Purchased Shares who derive their chain of ownership through a Permitted Transfer from
Optionee (the “Owner”) shall not (i) lend, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, any securities of the Company, including (without limitation) shares of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether now owned or
hereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of any securities of the Company, including (without limitation) shares of Common
Stock or any securities convertible into or exercisable or exchangeable for Common Stock (whether now owned or hereafter acquired), whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of
securities, in cash or otherwise without the prior written consent of the Company or its underwriters. Such restriction (the “Market Stand-Off”) shall be in effect for such period of time from and after the effective date of
the final prospectus for the offering as may be requested by the Company or such underwriters. In no event, however, shall such period exceed one hundred eighty (180) days, and the Market Stand-Off shall in no event be applicable to any
underwritten public offering effected more than two (2) years after the effective date of the Company’s initial public offering. 
 (b) Owner shall be subject to the Market Stand-Off provided and only if the officers and directors of the Company are also subject to similar restrictions. 

  
 Exhibit C -
Page 3 

 (c) Any new, substituted or additional securities which are by reason of any
Recapitalization or Reorganization distributed with respect to the Purchased Shares shall be immediately subject to the Market Stand-Off, to the same extent the Purchased Shares are at such time covered by such provisions. 

(d) In order to enforce the Market Stand-Off, the Company may impose stop-transfer instructions with respect to the
Purchased Shares until the end of the applicable stand-off period. 
  

	D.	REPURCHASE RIGHT 

 1.
Grant. The Company is hereby granted the right (the “Repurchase Right”), exercisable at any time during the sixty (60)-day period following the date Optionee ceases for any reason to remain in Service or (if later)
during the sixty (60)-day period following the execution date of this Agreement, to repurchase at the lower of (i) the Exercise Price or (ii) the Fair Market Value per share of Common Stock on the date of Optionee’s cessation of
Service (the “Repurchase Price”) any or all of the Purchased Shares in which Optionee is not, at the time of his or her cessation of Service, vested in accordance with the Vesting Schedule or the special vesting acceleration
provisions of Paragraph D.6 of this Agreement (such shares to be hereinafter referred to as the “Unvested Shares”). 
 2. Exercise of the Repurchase Right. The Repurchase Right shall be exercisable by written notice delivered to each Owner of the Unvested Shares prior to the expiration of the sixty (60)-day
exercise period. The notice shall indicate the number of Unvested Shares to be repurchased, the Repurchase Price to be paid per share and the date on which the repurchase is to be effected, such date to be not more than thirty (30) days after
the date of such notice. The certificates representing the Unvested Shares to be repurchased shall be delivered to the Company on the closing date specified for the repurchase. Concurrently with the receipt of such stock certificates, the Company
shall pay to Owner, in cash or cash equivalents (including the cancellation of any purchase-money indebtedness), an amount equal to the Repurchase Price for the Unvested Shares which are to be repurchased from Owner. 

3. Termination of the Repurchase Right. The Repurchase Right shall terminate with respect to any Unvested Shares for which it is
not timely exercised under Paragraph D.2. In addition, the Repurchase Right shall terminate and cease to be exercisable with respect to any and all Purchased Shares in which Optionee vests in accordance with the Vesting Schedule. All Purchased
Shares as to which the Repurchase Right lapses shall, however, remain subject to (i) the First Refusal Right and (ii) the Market Stand-Off. 
 4. Aggregate Vesting Limitation. If the Option is exercised in more than one increment so that Optionee is a party to one or more other Stock Purchase Agreements (the “Prior Purchase
Agreements”) which are executed prior to the date of this Agreement, then the total number of Purchased Shares as to which Optionee shall be deemed to have a fully-vested interest under this Agreement and all Prior Purchase Agreements
shall not exceed in the aggregate the number of Purchased Shares in which Optionee would otherwise at the time be vested, in accordance with the Vesting Schedule, had all the Purchased Shares (including those acquired under the Prior Purchase
Agreements) been acquired exclusively under this Agreement. 

  
 Exhibit C -
Page 4 

 5. Recapitalization. Any new, substituted or additional securities or other property
(including cash paid other than as a regular cash dividend) which is by reason of any Recapitalization distributed with respect to the Purchased Shares shall be immediately subject to the Repurchase Right and any escrow requirements hereunder, but
only to the extent the Purchased Shares are at the time covered by such right or escrow requirements. Appropriate adjustments to reflect such distribution shall be made to the number and/or class of Purchased Shares subject to this Agreement and to
the Repurchase Price per share to be paid upon the exercise of the Repurchase Right in order to reflect the effect of any such Recapitalization upon the Company’s capital structure; provided, however, that the aggregate Repurchase Price shall
remain the same. 
 6. Change in Control. 

(a) The Repurchase Right shall automatically terminate in its entirety, and all the Purchased Shares shall vest in full,
immediately prior to the consummation of any Change in Control, except to the extent the Repurchase Right is to be assigned to the successor entity in such Change in Control or otherwise continued in full force and effect pursuant to the terms of
the Change in Control transaction. 
 (b) To the extent the Repurchase Right remains in effect following a Change
in Control, such right shall apply to any new securities or other property (including any cash payments) received in exchange for the Purchased Shares in consummation of the Change in Control, but only to the extent the Purchased Shares are at the
time covered by such right. Appropriate adjustments shall be made to the Repurchase Price per share payable upon exercise of the Repurchase Right to reflect the effect (if any) of the Change in Control upon the Company’s capital structure;
provided, however, that the aggregate Repurchase Price shall remain the same. The new securities or other property (including any cash payments) issued or distributed with respect to the Purchased Shares in consummation of the Change in
Control shall be immediately deposited in escrow with the Company (or the successor entity) and shall not be released from escrow until Optionee vests in such securities or other property in accordance with the same Vesting Schedule in effect for
the Purchased Shares. 
  

	E.	RIGHT OF FIRST REFUSAL 

1. Grant. The Company is hereby granted the right of first refusal (the “First Refusal Right”), exercisable
in connection with any proposed transfer of the Purchased Shares in which Optionee has vested in accordance with the provisions of Article D. For purposes of this Article E, the term “transfer” shall include any
sale, assignment, pledge, encumbrance or other disposition of the Purchased Shares intended to be made by Owner, but shall not include any Permitted Transfer. 
 2. Notice of Intended Disposition. In the event any Owner of Purchased Shares in which Optionee has vested desires to accept a bona fide third-party offer for the transfer of any or all of such
shares (the Purchased Shares subject to such offer to be hereinafter referred to as the “Target Shares”), Owner shall promptly (i) deliver to the Company written notice (the “Disposition Notice”)
of the terms of the offer, including the purchase price and the identity of the third-party offeror, and (ii) provide satisfactory proof that the disposition of the Target Shares to such third-party offeror would not be in contravention of the
provisions set forth in Articles B and C. 

  
 Exhibit C -
Page 5 

 3. Exercise of the First Refusal Right. The Company shall, for a period of
twenty-five (25) days following receipt of the Disposition Notice, have the right to repurchase any or all of the Target Shares subject to the Disposition Notice upon the same terms as those specified therein or upon such other terms (not
materially different from those specified in the Disposition Notice) to which Owner consents. Such right shall be exercisable by delivery of written notice (the “Exercise Notice”) to Owner prior to the expiration of the
twenty-five (25)-day exercise period. If such right is exercised with respect to all the Target Shares, then the Company shall effect the repurchase of such shares, including payment of the purchase price, not more than five (5) business days
after delivery of the Exercise Notice; and at such time the certificates representing the Target Shares shall be delivered to the Company. 
 Should the purchase price specified in the Disposition Notice be payable in property other than cash or evidences of indebtedness, the Company shall have the right to pay the purchase price in the form of
cash equal in amount to the value of such property. If Owner and the Company cannot agree on such cash value within ten (10) days after the Company’s receipt of the Disposition Notice, the valuation shall be made by an appraiser of
recognized standing selected by Owner and the Company or, if they cannot agree on an appraiser within twenty (20) days after the Company’s receipt of the Disposition Notice, each shall select an appraiser of recognized standing and the two
(2) appraisers shall designate a third appraiser of recognized standing, whose appraisal shall be determinative of such value. The cost of such appraisal shall be shared equally by Owner and the Company. The closing shall then be held on the
later of (i) the fifth (5th) business day following delivery of the Exercise Notice or (ii) the fifth (5th) business day after such valuation shall have been made. 

4. Non-Exercise of the First Refusal Right. In the event the Exercise Notice is not given to Owner prior to the expiration of the
twenty-five (25)-day exercise period, Owner shall have a period of thirty (30) days thereafter in which to sell or otherwise dispose of the Target Shares to the third-party offeror identified in the Disposition Notice upon terms (including the
purchase price) no more favorable to such third-party offeror than those specified in the Disposition Notice; provided, however, that any such sale or disposition must not be effected in contravention of the provisions of Articles B and C. The
third-party offeror shall acquire the Target Shares subject to the First Refusal Right and the provisions and restrictions of Article B and Paragraph C.3, and any subsequent disposition of the acquired shares must be effected in compliance
with the terms and conditions of such First Refusal Right and the provisions and restrictions of Article B and Paragraph C.3. In the event Owner does not effect such sale or disposition of the Target Shares within the specified thirty
(30)-day period, the First Refusal Right shall continue to be applicable to any subsequent disposition of the Target Shares by Owner until such right lapses. 

  
 Exhibit C -
Page 6 

 5. Partial Exercise of the First Refusal Right. In the event the Company makes a
timely exercise of the First Refusal Right with respect to a portion, but not all, of the Target Shares specified in the Disposition Notice, Owner shall have the option, exercisable by written notice to the Company delivered within five
(5) business days after Owner’s receipt of the Exercise Notice, to effect the sale of the Target Shares pursuant to either of the following alternatives: 

(i) sale or other disposition of all the Target Shares to the third-party offeror identified in the Disposition Notice,
but in full compliance with the requirements of Paragraph E.4, as if the Company did not exercise the First Refusal Right; or 
 (ii) sale to the Company of the portion of the Target Shares which the Company has elected to purchase, such sale to be effected in substantial conformity with the provisions of Paragraph E.3. The
First Refusal Right shall continue to be applicable to any subsequent disposition of the remaining Target Shares until such right lapses. 
 Owner’s failure to deliver timely notification to the Company shall be deemed to be an election by Owner to sell the Target Shares pursuant to alternative (i) above. 

6. Recapitalization/Reorganization. 
 (a) Any new, substituted or additional securities or other property which is by reason of any Recapitalization distributed with respect to the Purchased Shares shall be immediately subject to the First
Refusal Right, but only to the extent the Purchased Shares are at the time covered by such right. 
 (b) In the
event of a Reorganization, the First Refusal Right shall remain in full force and effect and shall apply to the new capital stock or other property received in exchange for the Purchased Shares in consummation of the Reorganization, but only to the
extent the Purchased Shares are at the time covered by such right. 
 7. Lapse. The First Refusal Right shall lapse upon
the earliest to occur of (i) the first date on which shares of the Common Stock are held of record by more than five hundred (500) persons, (ii) a determination made by the Board that a public market exists for the outstanding shares
of Common Stock, (iii) a firm commitment underwritten public offering, pursuant to an effective registration statement under the 1933 Act, covering the offer and sale of the Common Stock in the aggregate amount of at least twenty million
dollars ($20,000,000) or (iv) the closing of a Change in Control. However, the Market Stand-Off shall continue to remain in full force and effect following the lapse of the First Refusal Right. 

 

	F.	SPECIAL TAX ELECTION 

 The
acquisition of the Purchased Shares may result in adverse tax consequences which may be avoided or mitigated by filing an election under Code Section 83(b). Such election must be filed within thirty (30) days after the date of this
Agreement. A description of the tax consequences applicable to the acquisition of the Purchased Shares and the form for making the Code Section 83(b) election are set forth in Exhibit II. OPTIONEE SHOULD CONSULT WITH HIS OR HER TAX
ADVISOR TO DETERMINE THE TAX CONSEQUENCES OF ACQUIRING THE PURCHASED SHARES AND THE ADVANTAGES AND DISADVANTAGES OF FILING THE CODE SECTION 83(b) ELECTION. OPTIONEE ACKNOWLEDGES THAT IT IS OPTIONEE’S SOLE RESPONSIBILITY, AND NOT THE
COMPANY’S, TO FILE A TIMELY ELECTION UNDER CODE SECTION 83(b), EVEN IF OPTIONEE REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON HIS OR HER BEHALF. 

  
 Exhibit C -
Page 7 

	G.	GENERAL PROVISIONS 

 1.
Assignment. The Company may assign the Repurchase Right and/or the First Refusal Right to any person or entity selected by the Board, including (without limitation) one or more stockholders of the Company. 

2. At Will Employment. Nothing in this Agreement or in the Plan shall confer upon Optionee any right to continue in Service for
any period of specific duration or interfere with or otherwise restrict in any way the rights of the Company (or any Parent or Subsidiary employing or retaining Optionee) or of Optionee, which rights are hereby expressly reserved by each, to
terminate Optionee’s Service at any time for any reason, with or without cause. 
 3. Notices. Any notice required
to be given under this Agreement shall be in writing and shall be deemed effective upon personal delivery or upon deposit in the U.S. mail, registered or certified, postage prepaid and properly addressed to the party entitled to such notice at the
address indicated below such party’s signature line on this Agreement or at such other address as such party may designate by ten (10) days advance written notice under this paragraph to all other parties to this Agreement. 

Optionee generally consents to the delivery of any notice pursuant to the Texas Business Organizations Code (the
“TBOC”), as amended or superseded from time to time, by electronic message pursuant to Section 6.051 of the TBOC (“Electronic Notice”) at the electronic mail address or the facsimile number as set
forth in the books of the Company. To the extent that any notice given via electronic message is returned or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected electronic mail address
has been provided, and such attempted Electronic Notice shall be ineffective and deemed to not have been given. Optionee agrees to promptly notify the Company of any change in Optionee’s electronic mail address, but failure to do so shall not
affect the foregoing. 
 4. No Waiver. The failure of the Company in any instance to exercise the Repurchase Right or the
First Refusal Right shall not constitute a waiver of any other repurchase rights and/or rights of first refusal that may subsequently arise under the provisions of this Agreement or any other agreement between the Company and Optionee. No waiver of
any breach or condition of this Agreement shall be deemed to be a waiver of any other or subsequent breach or condition, whether of like or different nature. 
 5. Cancellation of Shares. If the Company shall make available, at the time and place and in the amount and form provided in this Agreement, the consideration for the Purchased Shares to be
repurchased in accordance with the provisions of this Agreement, then from and after such time, the person from whom such shares are to be repurchased shall no longer have any rights as a holder of such shares (other than the right to receive
payment of such consideration in accordance with this Agreement). Such shares shall be deemed purchased in accordance with the applicable provisions hereof, and the Company shall be deemed the owner and holder of such shares, whether or not the
certificates therefor have been delivered as required by this Agreement. 

  
 Exhibit C -
Page 8 

	H.	MISCELLANEOUS PROVISIONS 

1. Optionee Undertaking. Optionee hereby agrees to take whatever additional action and execute whatever additional documents the
Company may deem necessary or advisable in order to carry out or effect one or more of the obligations or restrictions imposed on either Optionee or the Purchased Shares pursuant to the provisions of this Agreement. 

2. Agreement is Entire Contract. This Agreement constitutes the entire contract between the parties hereto with regard to the
subject matter hereof. This Agreement is made pursuant to the provisions of the Plan and shall in all respects be construed in conformity with the terms of the Plan. 
 3. Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Texas without resort to that state’s conflict-of-laws rules. 

4. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same instrument. 
 5. Successors and Assigns. The provisions of this Agreement
shall inure to the benefit of, and be binding upon, the Company and its successors and assigns and upon Optionee, Optionee’s permitted assigns and the legal representatives, heirs and legatees of Optionee’s estate, whether or not any such
person shall have become a party to this Agreement and have agreed in writing to join herein and be bound by the terms hereof. 

[Signature page follows] 

  
 Exhibit C -
Page 9 

 NON-EXEMPT EMPLOYEE 

IN WITNESS WHEREOF, the parties have executed this Stock Purchase Agreement on the day and year first indicated above. 

 

									
		 		 	WHITEGLOVE HOUSE CALL HEALTH, INC.
					
		 		 		 	By:	 	 
					
		 		 		 	Title:	 	 
					
		 		 		 	Address:	 	 
		 		 		 		 	 
				
		 		 		 	OPTIONEE
				
		 		 		 	 
		 		 		 	«name»	 	
					
		 		 		 	Address:	 	 
		 		 		 		 	 

  
 Exhibit C -
Page 1 

 SPOUSAL ACKNOWLEDGMENT 

The undersigned spouse of Optionee has read and hereby approves the foregoing Stock Purchase Agreement. In consideration of the
Company’s granting Optionee the right to acquire the Purchased Shares in accordance with the terms of such Agreement, the undersigned hereby agrees to be irrevocably bound by all the terms of such Agreement, including (without limitation) the
right of the Company (or its assigns) to purchase any Purchased Shares in which Optionee is not vested at time of his or her cessation of Service. 
  

			
	
	 
	OPTIONEE’S SPOUSE
		
	Address:	 	 
		 	 

 EXHIBIT I 
 ASSIGNMENT SEPARATE FROM CERTIFICATE 
 FOR VALUE RECEIVED
                             hereby sell(s), assign(s) and transfer(s) unto Whiteglove House Call
Health, Inc. (the “Company”),              (            ) shares of the Common Stock of the
Company standing in his or her name on the books of the Company represented by Certificate No.                      herewith and do(es) hereby
irrevocably constitute and appoint                      Attorney to transfer the said stock on the books of the Company with full power of
substitution in the premises. 
 Dated:
                     
  

			
		
	Signature	 	 

 Instruction:
Please do not fill in any blanks other than the signature line. Please sign exactly as you would like your name to appear on the issued stock certificate. The purpose of this assignment is to enable the Company to exercise the Repurchase Right
without requiring additional signatures on the part of Optionee. 

  
 Exhibit
C-1 

 EXHIBIT II 
 FEDERAL INCOME TAX CONSEQUENCES AND 
 SECTION 83(b) TAX ELECTION

 I. Federal Income Tax Consequences and Section 83(b) Election For Exercise of Non-Statutory Option. If the
Purchased Shares are acquired pursuant to the exercise of a Non-Statutory Option, as specified in the Grant Notice, then under Code Section 83, the excess of the Fair Market Value of the Purchased Shares on the date any forfeiture restrictions
applicable to such shares lapse over the Exercise Price paid for those shares will be reportable as ordinary income on the lapse date. For this purpose, the term “forfeiture restrictions” includes the right of the Company to
repurchase the Purchased Shares pursuant to the Repurchase Right. However, Optionee may elect under Code Section 83(b) to be taxed at the time the Purchased Shares are acquired, rather than when and as such Purchased Shares cease to be subject
to such forfeiture restrictions. Such election must be filed with the Internal Revenue Service within thirty (30) days after the date of the Agreement. Even if the Fair Market Value of the Purchased Shares on the date of the Agreement equals
the Exercise Price paid (and thus no tax is payable), the election must be made to avoid adverse tax consequences in the future. The form for making this election is attached as part of this exhibit. FAILURE TO MAKE THIS FILING WITHIN THE APPLICABLE
THIRTY (30)-DAY PERIOD WILL RESULT IN THE RECOGNITION OF ORDINARY INCOME BY OPTIONEE AS THE FORFEITURE RESTRICTIONS LAPSE. 

II. Federal Income Tax Consequences and Conditional Section 83(b) Election For Exercise of Incentive Option. If the Purchased
Shares are acquired pursuant to the exercise of an Incentive Option, as specified in the Grant Notice, then the following tax principles shall be applicable to the Purchased Shares: 

(i) For regular tax purposes, no taxable income will be recognized at the time the Option is exercised. 

(ii) The excess of (a) the Fair Market Value of the Purchased Shares on the date the Option is exercised or (if
later) on the date any forfeiture restrictions applicable to the Purchased Shares lapse over (b) the Exercise Price paid for the Purchased Shares will be includible in Optionee’s taxable income for alternative minimum tax purposes.

 (iii) If Optionee makes a disqualifying disposition of the Purchased Shares, then Optionee will recognize
ordinary income in the year of such disposition equal in amount to the excess of (a) the Fair Market Value of the Purchased Shares on the date the Option is exercised or (if later) on the date any forfeiture restrictions applicable to the
Purchased Shares lapse over (b) the Exercise Price paid for the Purchased Shares. Any additional gain recognized upon the disqualifying disposition will be either short-term or long-term capital gain depending upon the period for which the
Purchased Shares are held prior to the disposition. 

  
 Exhibit
C-II - Page 1 

 (iv) For purposes of the foregoing, the term
“forfeiture restrictions” will include the right of the Company to repurchase the Purchased Shares pursuant to the Repurchase Right. The term “disqualifying disposition” means any sale or other
disposition1 of the Purchased Shares within two (2) years after the Grant Date or within one (1) year after the exercise
date of the Option. 
 (v) The Code Section 83(b) election will be effective in limiting the Optionee’s
alternative minimum taxable income to the excess of the Fair Market Value of the Purchased Shares at the time the Option is exercised over the Exercise Price paid for those shares. 

Page 2 of the attached form for making the election should be filed with any election made in connection with the
exercise of an Incentive Option. 
  

	1 	 Generally, a disposition of shares purchased under an Incentive Option includes any transfer of legal title, including a transfer by sale, exchange or
gift, but does not include a transfer to the Optionee’s spouse, a transfer into joint ownership with right of survivorship if Optionee remains one of the joint owners, a pledge, a transfer by bequest or inheritance or certain tax-free exchanges
permitted under the Code. 

  
 Exhibit
C-II - Page 2 

 SECTION 83(b) ELECTION 

This statement is being made under Section 83(b) of the Internal Revenue Code, pursuant to Treas. Reg. Section 1.83-2.

  

	(1)	The taxpayer who performed the services is: 

 Name: 
 Address: 

Taxpayer Ident. No.: 
  

	(2)	The property with respect to which the election is being made is
                     shares of the common stock of Whiteglove House Call Health, Inc. 

 

	(3)	The property was issued on                      ,
            . 

  

	(4)	The taxable year in which the election is being made is the calendar year             .

  

	(5)	The property is subject to a repurchase right pursuant to which the issuer has the right to acquire the property at the lower of the purchase price paid per share or
the fair market value per share, if for any reason taxpayer’s service with the issuer terminates. The issuer’s repurchase right will lapse in a series of annual and monthly installments over a four (4)-year period ending on
            , 20    . 

  

	(6)	The fair market value at the time of transfer (determined without regard to any restriction other than a restriction which by its terms will never lapse) is
$             per share. 

  

	(7)	The amount paid for such property is $             per share. 

 

	(8)	A copy of this statement was furnished to Whiteglove House Call Health, Inc. for whom taxpayer rendered the services underlying the transfer of property.

  

	(9)	This statement is executed on                      ,
            . 

  

									
					
		 	 	 		 		 	 
		 	Taxpayer	 		 		 	Spouse (if any)

 This election must be filed with the
Internal Revenue Service Center with which taxpayer files his or her federal income tax returns and must be made within thirty (30) days after the execution date of the Stock Purchase Agreement. This filing should be made by registered or
certified mail, return receipt requested. Optionee must retain two (2) copies of the completed form for filing with his or her federal and state tax returns for the current tax year and an additional copy for his or her records. 

 THIS PAGE 2 IS TO BE ATTACHED TO ANY SECTION 83(b) ELECTION FILED IN CONNECTION WITH THE EXERCISE OF AN
INCENTIVE STOCK OPTION UNDER THE FEDERAL TAX LAWS. 
 The property described in the above Section 83(b) election is
comprised of shares of common stock acquired pursuant to the exercise of an incentive stock option under Section 422 of the Internal Revenue Code (the “Code”). Accordingly, the purpose of this election is to have the
alternative minimum taxable income attributable to the purchased shares measured by the amount by which the fair market value of such shares at the time of their transfer to the Taxpayer exceeds the purchase price paid for the shares. In the absence
of this election, such alternative minimum taxable income would be measured by the spread between the fair market value of the purchased shares and the purchase price which exists on the various lapse dates in effect for the forfeiture restrictions
applicable to such shares. 

 EXHIBIT D 

FORM OF 

2007 STOCK OPTION/STOCK ISSUANCE PLAN 

 WHITEGLOVE HOUSE CALL HEALTH, INC. 

SPECIAL ACCELERATION ADDENDUM 
 TO 
 STOCK OPTION AGREEMENT 

The following provisions are hereby incorporated into, and are hereby made a part of, that certain Stock Option Agreement (the
“Option Agreement”) by and between Whiteglove House Call Health, Inc., a Texas corporation (the “Company”), and «name» (“Optionee”) evidencing the stock option (the
“Option”) granted on «granted» to Optionee under the terms of the Company’s 2007 Stock Option/Stock Issuance Plan, as amended, and such provisions shall be effective immediately. All capitalized terms in this
Addendum, to the extent not otherwise defined herein, shall have the meanings assigned to them in the Option Agreement. 

ACCELERATION OF VESTING IN CONNECTION WITH CHANGE IN CONTROL 
 1.(A) If the Option, to the extent outstanding, shall be (a) assumed (pursuant to the Plan) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction
or (b) replaced with a cash retention program of the Company or any successor corporation which preserves the spread existing on the unvested option shares at the time of the Change in Control and provides for subsequent payout of that spread
in accordance with the same vesting schedule applicable to those unvested option shares, then 
  

	 	(1)	50% of the then-remaining unvested shares shall become vested shares (or their equivalent under the equivalent option or right substituted for the option); and

  

	 	(2)	if the Optionee’s service is Involuntarily Terminated (as defined below) at any time during the twelve month period following the consummation of the Change in
Control, all of the then-remaining unvested shares shall become immediately vested and immediately exercisable for a period of 90 days from the date of termination of employment or service, and the option shall terminate upon the expiration of such
period; 

 OR 
 (B) In the event that the successor corporation (or parent thereof) refuses to assume or substitute the option, the option shall become immediately vested and the option shall become immediately
exercisable for all of the shares subject to the option. 

 2. For purposes of this Acceleration Policy, Optionee’s Service is “Involuntarily
Terminated” by reason of: 
  

	 	(1)	Optionee’s involuntary dismissal or discharge for reasons other than for Misconduct, or 

 

	 	(2)	Optionee’s voluntary resignation following (A) a change in Optionee’s position with the Company (or Parent or Subsidiary employing Optionee) which
materially reduces Optionee’s duties and responsibilities or the level of management to which he or she reports, (B) a reduction in Optionee’s level of compensation (including base salary, fringe benefits and target bonus under any
corporate-performance based incentive programs) by more than fifteen percent (15%) or (C) a relocation of Optionee’s place of employment by more than fifty (50) miles, provided and only if such change, reduction or relocation is
effected by the Company without Optionee’s consent. 

 3. The provisions of this Addendum shall govern the
period for which the Option is to remain exercisable following the Involuntary Termination of Optionee’s Service after the Change in Control and shall supersede any provisions to the contrary in the Option Agreement, including those concerning
the deferred exercisability of the Option. 
 IN WITNESS WHEREOF, Whiteglove House Call Health, Inc. has caused this
Addendum to be executed by its duly-authorized officer as of the Effective Date specified below. 
  

			
	WHITEGLOVE HOUSE CALL HEALTH, INC.
	
	 
	By:	 	Robert A. Fabbio
		 	President

 EFFECTIVE DATE:
                     ,Medical Director Agreement

 Exhibit 10.12 
 June 15, 2007 
 MEDICAL DIRECTOR AGREEMENT 

THIS MEDICAL DIRECTOR AGREEMENT (this “Agreement”) is entered into this 18th day of June, 2007 (the
“Effective Date”), by and between WhiteGlove House Call Health, Inc., a Texas corporation (“Company”), and William Rice, M.D. (“Physician”) 

RECITALS: 

WHEREAS, Company provides healthcare services to individuals in their homes and offices through licensed nurse practitioners;

 WHEREAS, Company desires to engage Physician to provide medical director services, including appropriate supervision
of nurse practitioners; 
 WHEREAS, Physician, who is duly licensed in the State of Texas and qualified to provide the
medical director services, desires to serve in the position of medical director of Company in accordance with the terms and conditions of this Agreement. 
 NOW, THEREFORE, in consideration of the mutual promises and covenants entered into and other good and valuable consideration, the sufficiency and adequacy of which is hereby acknowledged, the
parties hereto agree to the following terms and conditions: 
  

	I.	Scope of Services 

  

	 	1.1	Company hereby engages and retains Physician to provide the Services (defined below) described herein. 

 

	 	1.2	Physician hereby accepts such engagement and agrees to provide the Services described herein. Physician shall provide the Services in a professional manner.

  

	II.	Responsibilities of Company 

  

	 	2.1	Company shall furnish Physician with reasonable administrative support to accomplish his duties and responsibilities under this Agreement, but not in support of
Physician’s activities beyond the scope of this Agreement. 

  

	 	2.2	Company shall periodically evaluate Physician’s performance under this Agreement. 

 

	III.	Responsibilities of Physician 

  

	 	3.1	Physician agrees to devote such time, energy and skill, as its duties hereunder shall require. 

 

	 	3.2	Physician shall be responsible for overall supervision of healthcare services to Company’s patients, including without limitation the following services (the
“Services”): 

  

	 	3.2.1	Provide medical input into policy and procedure development and review new protocols for all medical care; 

	 	3.2.2	Function as the Company Administrator (“Administrator”) to participate in the oversight of activities, including, but not limited to,
budgets, planning, research, cooperative arrangements with other health care facilities and staffing; 

  

	 	3.2.3	Provide clinical direction, including required supervision and delegation, to Company’s nurse practitioners and other non-physician personnel;

  

	 	3.2.4	Attend and participate in committee meetings as requested by Company; 

  

	 	3.2.5	Participate in regular meetings with the Alternate Administrator, Nurse Supervisor and others as necessary to ensure regular communication with and effective management
of Company. 

  

	 	3.2.6	Participate in educational programs as necessary to maintain expertise in physician’s specialty; 

 

	 	3.2.7	Assure availability of physician services for oversight and management of clinical matters; 

 

	 	3.2.8	Participate in performance improvement, audits and utilization review activities as requested by Company and make recommendations as needed; 

 

	 	3.2.9	Provide staff in-service education on topics relevant to Company patients as requested by Company; and 

 

	 	3.2.10	Participate, manage, and delegate, as appropriate, the interviewing, recruitment, and hiring of all nurse practitioners and other clinical staff.

  

	 	3.3	Records and Reports. As part of the Services, Physician shall also maintain such records and furnish such reports of services as may be requested by Company.
Physician shall submit monthly time records, in the form attached hereto as Exhibit A, satisfactory to the Company’s office manager, for Physician’s services under this Agreement. 

 

	 	3.4	Qualifications of Physician. 

  

	 	3.4.1	Licenses/Permits. Physician at all times during the term of this Agreement shall: (1) possess an active license in good standing to practice medicine in
Texas (2) possess active unrestricted federal and state DEA registration. 

  

	 	3.4.2	Compliance With Laws, Regulations and Standards. Physician shall comply with the standards and requirements of all applicable federal, state, local and other
laws, rules and regulations governing the Services, applicable professional standards and all applicable Company policies and procedures, including Company’s compliance program. 

 

	IV.	Representations and Warranties 

 Physician represents and warrants that: 
  

	 	4.1	Physician has never had his license or right to practice medicine in Texas or any other state, or his clinical privileges at any hospital or health care facility,
suspended, revoked, or limited in any way, nor has he ever surrendered his license or clinical privileges under threat of any such suspension, revocation or limitation. 

  
 2 

	 	4.2	Physician is not currently and has not been suspended from participation in or subject to any type of criminal or civil sanction, fine, civil money penalty, exclusion
or other penalty by any private or public health insurance program, including Medicare, Medicaid or any other federal or state health insurance program. 

  

	 	4.3	There are no proceedings pending or threatened against Physician relating to his license or right to practice medicine in Texas or any other state, his clinical
privileges at any hospital or other health care facility, or any professional services provided by Physician. 

  

	V.	Compensation 

  

	 	5.1	 As sole consideration for the Services provided hereunder, during the term of this Agreement, Company will pay Physician $12,500.00 per month, paid
bi-weekly, commencing on January 1, 2008. Physician shall provide monthly timesheets accounting for the number of hours spent providing Services by the tenth (10th) day of each month. Company shall remit payment to Physician within fifteen (15) days of receiving and
verifying each completed time sheet. The parties acknowledge and agree that the compensation to be paid hereunder is fair market value for the Services. 

 

	VI.	Insurance 

  

	 	6.1	The Company shall maintain comprehensive professional and general liability insurance at levels required by law, but not less than $1 million per occurrence and $3
million in the aggregate, that will cover Physician for services rendered on behalf of the Company. 

  

	VII.	Term And Termination 

  

	 	7.1	The initial term of this Agreement shall be one year beginning with the Effective Date, and this Agreement shall automatically renew for additional one-year terms,
unless sooner terminated as provided in this Section of the Agreement. The parties agree to review and assess the terms of this Agreement annually. 

  

	 	7.2	This Agreement may be terminated as follows: 

  

	 	7.2.1	Company may terminate this Agreement at any time upon thirty (30) days’ prior written notice. 

 

	 	7.2.2	Either party may terminate this Agreement due to a material breach of any term of this Agreement by the other party upon written notice of such breach to the breaching
party, and the failure of the breaching party to cure such breach within thirty (30) days after receiving such notice. 

  

	 	7.2.3	Notwithstanding any other provision in this Agreement, Company shall have a right to terminate this Agreement immediately in the event of the occurrence of any one of
the following: 

  

	 	(a)	The suspension, revocation or limitation of Physician’s license to practice medicine; 

  
 3 

	 	(b)	The loss or suspension of Physician’s federal or state registrations to prescribe and dispense controlled substances; 

 

	 	(c)	A determination by Company, in its reasonable discretion, that Physician has committed professional misconduct; 

 

	 	(d)	The death of Physician; 

  

	 	(e)	The conviction of Physician, in any jurisdiction, of a felony or crime of moral turpitude; 

 

	 	(f)	Physician sells his shares or otherwise ceases to be an owner of Company; or 

 

	 	(g)	Physician becomes disabled or impaired to the extent that he is unable to perform the duties required under this Agreement. 

 

	 	7.2.4	In the event of a change in laws, regulations or the method or amount of reimbursement which materially adversely affects the economic benefit expected by either party
under the terms this Agreement, a party, if it has been or will be materially adversely affected, shall have the right to request that the other party negotiate a modification to any of the terms of this Agreement to the extent and in the manner
reasonably necessary to accommodate such governmental action and to preserve the economic benefits hereof. If the parties are unable to reach an agreement concerning modification of this Agreement within thirty (30) days, either party may
immediately terminate this Agreement upon written notice to the other party. 

  

	 	7.3	Upon termination of this Agreement for any reason, no party shall have any further obligation hereunder except for (1) obligations which accrued prior to the date
of termination and (2) obligations, promises or covenants contained herein that expressly extend beyond the term of this Agreement. In the event that this Agreement is terminated prior to the end of any one-year term, the parties shall not
enter into another contract with each other for the same or similar services within the remaining period of such one-year term of this Agreement. 

  

	VIII.	General Provisions 

  

	 	8.1	Compliance with Policies. Physician shall comply with Company’s corporate compliance plan, and all service standards, clinical protocols, policies and
procedures developed and implemented by the Company, as the same may be modified from time to time. 

  

	 	8.2	Independent Contractor. All work performed by Physician in connection with the Services shall be performed by Physician as an independent contractor and not as
the agent or employee of Company. Physician shall perform the Services required under this Agreement according to his own means and methods, which shall be the exclusive charge of Physician. Nothing contained in this Agreement shall be construed as
giving Company control over the professional judgment of Physician. 

  
 4 

	 	8.3	Modifications. No addition or modification to this Agreement is valid unless in writing and executed by the parties. 

 

	 	8.4	Governing Law; Venue. This Agreement is governed by the laws of the State of Texas and venue for any action pursuant to this Agreement shall be in the county in
which Company operates. 

  

	 	8.5	Severability. In the event that any one or more of the provisions of this Agreement shall for any reason be held to be invalid, illegal or unenforceable, the
invalidity, illegality, or unenforceability shall not affect any other provision, and the Agreement shall be construed as though it had not contained the invalid, illegal, or unenforceable provision. 

 

	 	8.6	Waiver. Any failure by either party at any time to enforce or require the strict performance of any of the terms or conditions hereof shall not constitute a
waiver of its rights and shall not affect or impair either party’s right to avail itself of the remedies available for subsequent breach of such terms or conditions. 

 

	 	8.7	Section Headings. Section headings are added solely to aid in the review of this Agreement and are not to be construed to affect the interpretation of this
Agreement. 

  

	 	8.8	Assignment; Subcontracting. Physician shall not assign this Agreement nor his interest therein without the prior written consent of Company. Physician is
prohibited from subcontracting for any portion of the Services without prior written approval of Company. 

  

	 	8.9	Binding Agreement. This Agreement shall be binding upon and inure to the benefit of Company, its successors and assigns, and shall be binding upon and inure to
the benefit of Physician, his successors and permitted assigns. 

  

	 	8.10	Notice. Any notice required to be given under this Agreement shall be effective on the date of delivery if personally delivered, on the next business day, if
delivered by Federal Express or other equivalent overnight courier, or on the third business day after mailing, first-class, postage pre-paid to: Company at 1250 Capital of Texas Highway South, Building 3, Suite 400, Austin, TX 78746 and Physician
at 3601 Travis Country Circle, Austin, TX, 78735. 

  

	 	8.11	Compliance with Laws. Physician covenants to comply with all local, state and federal laws, rules and regulations in its performance of its duties and
obligations hereunder, including but not limited to obtaining and maintaining appropriate permits and licenses, and maintaining the privacy, confidentiality and security of protected health information as required under federal and state laws and
regulations. 

  

	 	8.12	 Confidential Information. In order to assist Physician in the performance of this Agreement, Company may provide Physician with confidential
information including, but not limited to, business plans, financials, customer information, trade secrets, trademarks, trade names, drawings, formulas, patterns, masks, models, devices, computer programs, secret inventions, processes, and
compilations of information, records, and specifications which are owned by Company or available to Company under contracts or agreements with third parties (hereafter “Company Confidential Information”). Physician may learn, during the
term of this Agreement, product or marketing strategies of Company or its customers or prospects, contractual relations between Company and its 

  
 5 

	 	 
customers or prospects, product development schedules or announcement information, or related proprietary information which is confidential to Company or its clients and such information is also
classified as “Company Confidential Information”. Physician shall use at least the same degree of care to protect and prevent unauthorized disclosure of any Company Confidential Information as he would use to protect and prevent
unauthorized disclosures of his own proprietary information unless such information (a) was known to Physician prior to receipt of the information directly or indirectly from Company, or (b) is known or becomes known to Physician through
no act or failure to act on the part of Physician or of any person under any obligation of confidentiality to Company, or (c) is known or becomes generally known or available to the public. Physician shall use Company Confidential Information
only in the performance of this Agreement. No other use of Company Confidential Information, whether for Company’s benefit or for the benefit of others, is authorized. In no event is Physician authorized to disclose Company Confidential
Information without the prior written approval of Company. The terms of this Section shall be binding during and subsequent to Termination Date for a period of two (2) years. This Section 8.12 shall survive the expiration or termination of
this Agreement. 

  

	 	8.13	Property. All Company Confidential Information referred to in Section 8.12 and any other work produced by Company or any other work produced for Company by
Physician alone or with others or any Company information that comes into the Physician’s possession shall remain the sole and exclusive property of Company and shall not be removed from Company’s premises without Company’s consent.
Physician shall return to Company all such Company property obtained during the course of this Agreement when this Agreement terminates or at such earlier time as might be requested by Company. Company shall have the sole right to use, sell,
license, publish, or otherwise disseminate or transfer rights in work prepared by Physician pursuant to the performance of this Agreement. 

  

	 	8.14	Inventions. All work produced pursuant to this Agreement, whether produced by Physician alone or with others, shall be considered work made for hire and the sole
property of Company. Physician shall, during and subsequent to the term of this Agreement, communicate to Company all inventions, designs, improvements, processes, models or discoveries made or conceived in connection with any project or work
assignment performed pursuant to this Agreement, whether conceived by Physician alone or with others. Physician shall assign to Company, without further consideration or compensation, all right, title, and interest in such inventions, designs,
improvements, or discoveries. Physician shall also provide Company, at Company’s expense, all necessary assistance to obtain and maintain any and all notions, patents for these inventions, designs, improvements, or discoveries and vest Company
with full and exclusive title to all patents. All inventions, designs, improvements, or discoveries covered by this Section shall be and remain the property of Company, whether or not patented. 

 

	 	8.15	Copyrights, Trademarks. All work produced pursuant to this Agreement, whether produced by Physician alone or with others, shall be considered work made for hire
and the sole property of Company. Physician shall, during and subsequent to the term of this Agreement, assign to Company without further consideration all right, title, and interest in all trademarks and trade names and registration thereof,
copyrights and registration, extensions, and renewals thereof on all such material, including any translations performed pursuant to this Agreement. All materials produced under this Agreement shall be and remain the exclusive property of Company
whether or not registered. 

  
 6 

	 	8.16	Non-Compete and Non-Solicitation. 

  

	 	8.16.1	Physician agrees that during the term of this Agreement and for one (1) year after the termination date, Physician will not, without the Company’s express
written consent: (i) directly or indirectly, for himself or on behalf of any other person, corporation, or entity, seek to employ, solicit, encourage, or attempt to induce to leave, any (A) current employee or consultant of Company, or
(B) any person who, at any time during the three months prior to the termination date, was an employee or consultant of Company, or (ii) solicit the business of any then current (at the time of the termination date) clients or customers
(including parties which Company is engaged in business discussions) of Company relating, directly or indirectly, to the business of the company or competitive with the business of the Company, other than on behalf of Company, within a sixty
(60) mile radius of any Company location where Physician actually performed services for Company. 

  

	 	8.16.2	This non-competition provision shall not, however, prevent Physician from continuing care or treatment to a specific patient or patients during the course of an acute
illness even after the termination date or the end of the employment relationship with the Company. Moreover, nothing in this section is intended to prevent the Physician from obtaining a list of the names of the patients’ that were seen by the
Physician in the one year period preceding the date that this Agreement is terminated or that the Physician’s relationship with the Company is terminated. Finally, this section is not intended to restrict or otherwise limit access to medical
records of patients cared for by the Physician upon presentation of a written authorization executed by the patient and in a form acceptable to the Company along with payment of a reasonable fee for reproduction of such records as authorized by the
Texas State Board of Medical Examiners under §159.008 of the Texas Occupations Code. 

  

	 	8.16.3	In the event of a breach of this non-competition provision, Physician understands and agrees that the Company would be irreparably injured and without adequate remedy
of law. Therefore in an event of such a breach, the Company shall be entitled to enforce, in addition to any other remedies made available to it by law or equity, a temporary and/or permanent injunction and a decree for the specific performance of
the terms of this section, without the necessity of realizing an actual or threatened harm, and without being required to furnish a bond or other security. 

 

	 	8.16.4	Physician may have an option to buyout the terms of this covenant of non competition as allowed for under §15.50 of the Texas Labor Code. The price to be paid for
buying out the terms of this covenant shall be reasonable, or at the option of either party, as determined by a mutually agreed upon arbitrator, or, in the event that an arbitrator cannot be agreed to, an arbitrator assigned by the court whose
decision shall be binding on the parties. The cost for obtaining the services of the arbitrator shall be the responsibility of both parties in equal amounts except that any attorneys fees caused by either party shall be the sole responsibility of
the party who retained the counsel of the attorney. 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have caused this instrument to be executed by themselves or
their duly authorized officer as of the day, month and year first above written. 
  

							
	WHITEGLOVE HOUSE CALL HEALTH, INC.	 		 	PHYSICIAN
				
	By:	 	/s/ Robert Fabbio	 		 	/s/ William Rice
	Name:	 	Robert Fabbio	 		 	William Rice, M.D.
	Title:	 	CEO	 		 	

  
 8 

 EXHIBIT A 

MONTHLY TIME REPORT 
                                  
        [Month/Year] 
  

					
	 Administrative Duties
	  	Monthly Hours Worked	 
	Leadership Activities: Review clinical policies and procedures; assist in development and implementation of quality improvement activities; assist in development of new
services; provide clinical staff educational and training programs.	  			
		
	Advisory Activities: Advise with respect to clinical protocols, budgets, planning, research programs, outreach, staffing and other activities of Company.	  			
		
	Supervisory Activities: Supervise Nurse Practitioners, including on site supervision, review of medical records, etc.	  			
		
	 Meetings: Participate in regular meetings of
                     Committee
	  			
		
	 Other:
	  			
		
	 Total Hours Worked:
	  			

  

									
	By:	 	 	 		 	By:	 	 
		 	William Rice, M.D.	 		 		 	 WHITEGLOVE HOUSE CALL HEALTH, INC.

[Office Manager]

					
	Dated:	 	 	 		 	Dated:	 	 

  
 9 

 January 29, 2008 

MEDICAL DIRECTOR AGREEMENT AMENDMENT 
 THIS MEDICAL DIRECTOR AGREEMENT AMENDMENT (this “Agreement”) is entered into this 1st day of January, 2008 (the “Effective Date”), by and between WhiteGlove House
Call Health, Inc., a Texas corporation (“Company”), and William Rice, M.D. (“Physician”) 
 RECITALS: 
 WHEREAS, the parties have previously entered into an Medical Director
Agreement dated June 18, 2007 (“MD Agreement”); 
 WHEREAS, the parties wish to amend the MD Agreement by entering into
this Agreement where the terms and conditions of said MD Agreement remain in full force and effect and are only modified to the extent of this Agreement. 
 Replace the Compensation provision of the MD Agreement in entirety with the following: 
  

	V.	Compensation 

  

	 	5.1	 As sole consideration for the Services provided hereunder, during the term of this Agreement, Company will pay Physician $12,500.00 per month, paid
bi-weekly, commencing on December 31, 2008. In the event that the Company raises outside capital during 2008, the Company will commence paying the Physician within thirty (30) days of raising the outside funding. Physician shall provide
monthly timesheets accounting for the number of hours spent providing Services by the tenth (10th) day of each month. Company shall remit payment to Physician within fifteen (15) days of receiving and verifying each completed time sheet. The parties acknowledge and agree that the
compensation to be paid hereunder is fair market value for the Services. 

 IN WITNESS WHEREOF, the parties hereto have
caused this instrument to be executed by themselves or their duly authorized officer as of the day, month and year first above written. 
  

							
	WHITEGLOVE HOUSE CALL HEALTH, INC.	 		 	PHYSICIAN
				
	By:	 	/s/ Robert Fabbio	 		 	/s/ William Rice
	Name:	 	Robert Fabbio	 		 	William Rice, M.D.
	Title:	 	CEO	 		 	

  
 1 

 AMENDMENT OF MEDICAL DIRECTOR AGREEMENT 

This Amendment is made this 31 day of January, 2011, in Austin, Texas, by and between WhiteGlove House Call Health, Inc., a Texas
corporation (“Company”), and William Rice, M.D. (“Physician”). 
 RECITALS 

WHEREAS, the parties previously entered into a Medical Director Agreement on June 18, 2007, whereby Company retained
Physician to provide medical director services (“Original Medical Director Agreement”); and 
 WHEREAS,
the parties previously amended the Original Medical Director Agreement on January 29, 2008, April 30, 2008, August 15, 2008, and October 14, 2009 (“Amendments”); and 

WHEREAS, the Original Medical Director Agreement together with the Amendments constituted the Medical Director Agreement
(“Medical Director Agreement”); and 
 WHEREAS, the parties desire to revise certain provisions of the
Medical Director Agreement as set forth in this Amendment; and 
 NOW THEREFORE, in consideration of the
parties’ continuing obligations, the parties agree to revise the Medical Director Agreement as follows and that the provisions of the Medical Director Agreement that are not revised in this Amendment shall continue in effect as stated in the
Medical Director Agreement: 
  

	1.	Section 8.1.6.1 and 8.1.6.2 of the Medical Director Agreement is revised to read as follows: 

8.1.6.1 Physician agrees that during the term of this Agreement and for one (1) year after the termination date, Physician will not,
without the Company’s express written consent: (i) directly or indirectly, for himself or on behalf of any other person, corporation, or entity, seek to employ, solicit, encourage, or attempt to induce to leave, any (A) current
employee or consultant of Company, or (B) any person who, at any time during the three months prior to the termination date, was an employee or consultant of Company; (ii) solicit the business of any then current (at the time of the
termination date) clients or customers (including parties which Company is engaged in business discussions) of Company relating, directly or indirectly, to the business of the company or competitive with the business of the Company, other than on
behalf of Company, within a sixty (60) mile radius of any Company location where Physician actually performed services for Company; (iii) directly or indirectly acquire or hold any ownership or investment interest in or contract to provide
administrative or executive services to any person or entity providing the same or similar services that is directly competitive with the Company or (iv) otherwise compete with Company directly or in

  

			
	Amendment of Medical Director Agreement	  	Page 1

 
conjunction with any other person or entity. Nothing in this non-competition provision shall prohibit Physician from engaging in the practice of medicine in a clinical or executive capacity in an
office-based or hospital-based practice following the termination of this Agreement. 
 8.1.6.2 This non-competition provision
shall in no way be construed to prevent Physician from continuing care or treatment to a specific patient or patients during the course of an acute illness even after the termination date or the end of the relationship with the Company. Moreover,
nothing in this is intended to prevent the Physician from obtaining a list of the names of the patients that were seen by the Physician in the one year period preceding the date that this Agreement is terminated or that the Physician’s
relationship with Company is terminated. Finally, this Section is not intended to restrict or otherwise limit access to medical records of patients cared for by the Physician upon presentation of a written authorization executed by the patient and
in a form acceptable to Company along with payment of a reasonable fee for reproduction of such records as authorized by the Texas Medical Board under §159.008 of the Texas Occupations Code. 

IN WITNESS WHEREOF, the parties hereto have caused this instrument to be executed by themselves or their duly authorized officer
as of the day, month and year first above written. 
  

							
	WHITEGLOVE HOUSE CALL HEALTH, INC.	 		 	PHYSICIAN
				
	BY:	 	/s/ Robert Fabbio	 		 	/s/ William Rice
	NAME:	 	Robert Fabbio	 		 	William Rice, M.D.
	TITLE:	 	CEO	 		 	
	DATE:	 	1/31/11	 		 	

  

			
	Amendment of Medical Director Agreement	  	Page 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00188-of-00352.parquet"}]]